Mobocertinib, a novel targeted therapy, resulted in clinically meaningful improvement in core lung cancer symptoms and maintained general HRQoL in patients with EGFR ex20ins+ mNSCLC. The gene discussed is EGFR; the disease is lung carcinoma.